Modulation Of Sialidases In Pancreatic Cancer

<p>Pancreatic cancer is one of the deadliest forms of cancer with a very low survival rate. Sialidases are enzymes that play a key role in cancer progression by cleaving sialic acid residues from glycoproteins and glycolipids. The modulation of sialidases in pancreatic cancer has gained considerable attention as a potential therapeutic target for inhibiting tumor growth invasion and metastasis.</p><p>In recent years research has focused on understanding the mechanisms of sialidase modulation and its impact on tumor biology. Studies have identified sialylated glycans and tumor-associated carbohydrate antigens as important biomarkers for diagnosis and prognosis. Additionally sialidase modulation has been shown to affect cancer cell signaling pathways apoptosis chemoresistance and immune response.</p><p>The tumor microenvironment including extracellular matrix stromal cells and immune cells plays a critical role in pancreatic cancer progression. Sialidase modulation has been shown to impact the tumor microenvironment by influencing the behavior of cancer-associated fibroblasts tumor-infiltrating lymphocytes and angiogenesis.</p><p>Emerging evidence suggests that sialidase modulation may have significant implications for personalized cancer treatment and precision medicine. Furthermore the identification of novel therapeutic targets and the development of glycan-targeted therapeutics offer exciting prospects for the development of new and effective treatments for pancreatic cancer.</p>